生物学是女王:瘤型DX21基因复发率比淋巴结负担对乳腺癌患者具有更强的预后能力
在PubMed上查看摘要
概括
此摘要是机器生成的。在激素受体阳性乳腺癌中,瘤型DX21基因复发率 (RS) 是比淋巴结状况更强的生存指标. 结合生物 (RS) 和解剖学 (+ LNs) 因素可以改善生存预测,这可能会影响治疗决策.
科学领域
- 癌症学
- 基因组学
- 生物统计学
背景情况
- 乳腺癌的治疗越来越依赖于生物因素,但下淋巴结解剖 (ALND) 的决定仍然使用解剖学信息.
- 该研究调查了21基因复发得分 (RS) 或阳性淋巴结 (+ LNs) 是否更好地预测整体存活率 (OS).
研究的目的
- 在HR+/ HER2乳腺癌中,将瘤型DX复发评分 (RS) 与阳性淋巴结数 (+ LN) 的预测能力进行比较.
- 评估生物因素 (RS) 在预测结果方面是否比解剖因素 (LN状态) 有更大的影响.
- 为了告知下淋巴结解剖 (ALND) 的潜在缓解.
主要方法
- 使用国家癌症数据库 (NCDB) 对非转移性HR+/HER2-乳腺癌和可用RS的患者进行前期手术 (2018-2019).
- 使用卡普兰-梅尔曲线总结临床特征和估计的整体存活期 (OS).
- 进行回归分析以评估RS和+LN与OS的独立和联合关联.
主要成果
- 在71,235名患者中,较高的RS (> 25) 和更多的+LNs显著与更糟糕的生存状况相关.
- 在大多数淋巴结类别中,RS>25比+LNs的数量更强烈地预测OS.
- 一个结合RS和+LNs的模型显示了比单独的任何一个因素更强大的OS预测.
结论
- 在HR+/ HER2乳腺癌中,21基因复发率 (RS) 是比淋巴结状况更有力的死亡预测指标.
- 像RS这样的生物学因素可能比解剖学因素 (LN状态) 有更大的预后意义.
- 虽然RS是一个强有力的预测因素,但目前的数据尚未支持省略带淋巴结解剖 (ALND).
相关概念视频
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

